1 – 10 of 11
- show: 10
- |
- sort: year (new to old)
Close
Embed this list
<iframe src=" "
width=" "
height=" "
allowtransparency="true"
frameborder="0">
</iframe>
- 2024
-
Mark
Survival of patients with ruptured gastrointestinal stromal tumour treated with adjuvant imatinib in a randomised trial
(
- Contribution to journal › Article
- 2023
-
Mark
KIT and PDGFRA Mutations and Survival of Gastrointestinal Stromal Tumor Patients Treated with Adjuvant Imatinib in a Randomized Trial
(
- Contribution to journal › Article
- 2022
-
Mark
Fibrinogen-like protein 2 in gastrointestinal stromal tumour
(
- Contribution to journal › Article
- 2020
-
Mark
Survival Outcomes Associated with 3 Years vs 1 Year of Adjuvant Imatinib for Patients with High-Risk Gastrointestinal Stromal Tumors : An Analysis of a Randomized Clinical Trial after 10-Year Follow-up
(
- Contribution to journal › Article
- 2018
-
Mark
Expression of cell cycle regulators and frequency of TP53 mutations in high risk gastrointestinal stromal tumors prior to adjuvant imatinib treatment
(
- Contribution to journal › Article
- 2017
-
Mark
SLUG transcription factor : A pro-survival and prognostic factor in gastrointestinal stromal tumour
(
- Contribution to journal › Article
-
Mark
Effect of KIT and PDGFRA mutations on survival in patients with gastrointestinal stromal tumors treated with adjuvant imatinib : An exploratory analysis of a randomized clinical trial
(
- Contribution to journal › Article
- 2016
-
Mark
Adjuvant Imatinib for High-Risk GI Stromal Tumor: Analysis of a Randomized Trial.
(
- Contribution to journal › Article
- 2014
-
Mark
Risk Factors for Gastrointestinal Stromal Tumor Recurrence in Patients Treated With Adjuvant Imatinib
(
- Contribution to journal › Article
-
Mark
Bone sarcomas : ESMO clinical practice guidelines for diagnosis, treatment and follow-up
(
- Contribution to journal › Article